Clinical trials: Lung Tumors
Lung Neoplasms
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris…
- Trial name
- NCT05299606
- Testing
- Transbronchial Microwave Ablation
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 12 people
- Sponsor
- Ethicon, Inc.
Advanced Solid Tumors, Ovarian Cancer
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT02367352
- Testing
- Alisertib, Paclitaxel
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial
For patients diagnosed with early stage Non-Small Cell Lung Cancer (NSCLC) on preoperative computerized tomography (CT) and positron emission tomography (PET) scans, surgical resection is usually the preferred method of…
- Trial name
- CLNS (NCT03859349)
- Testing
- Selective Targeted Sampling, Systematic Sampling
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Small Cell Lung Cancer, Lung Cancer
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Standard of care for Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) as first-line treatment is 4 to 6 cycles of platinum based chemotherapy (carboplatin or cisplatin) in combination with etoposide.
- Trial name
- NCT04472949
- Testing
- Durvalumab, carboplatin, etoposide
- Where
- 14 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Non-Small Cell Lung Cancer
Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer
The purpose of this study is to validate TNM-Immunoscore in resected non-small cell lung cancer.
- Trial name
- TNM-I (NCT03299478)
- Testing
- Will look for immune infiltration
- Where
- 5 sites in Denmark, Norway
- Volunteers
- 865 people
- Sponsor
- University Hospital of North Norway
Malnutrition, Cancer
Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients
This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition…
- Conditions
- Malnutrition, Cancer, Inflammatory Bowel Diseases, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06055543
- Testing
- Fortimel
- Where
- 6 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Danone Specialized Nutrition
Cancer., Melanoma.
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined with the adjuvant MPLA from B.
- Conditions
- Cancer., Melanoma., Ovarian Cancer., Lung Cancer.
- Trial name
- NCT01584115
- Testing
- NY-ESO-1 combined with MPLA, NY-ESO-1 combined with MPLA vaccine
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigação em Imunologia
Breast Cancer, Lung Cancer
Pilot Study of a Pharmacy Intervention for Older Adults With Cancer
The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer.
- Conditions
- Breast Cancer, Lung Cancer, GI Cancer
- Trial name
- NCT02871115
- Testing
- Pharmacy Intervention, Usual Care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Lung Cancer
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast…
- Conditions
- Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer
- Trial name
- NCT06384417
- Testing
- Hello for Cancer game, Table Topics game
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Milton S. Hershey Medical Center
Non-Small-Cell Lung Cancer
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC
This study aims to evaluate the efficacy and safety of SBRT combined with Puterizumab immunotherapy for non-small cell lung cancer with pulmonary metastases, and to determine the correlation between MRD and treatment efficacy.
- Trial name
- NCT06434740
- Testing
- Stereotactic Body Radiation Therapy，SBRT, Puterizumab
- Volunteers
- 37 people
- Sponsor
- Sir Run Run Shaw Hospital
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00287989
- Testing
- Carboplatin, erlotinib hydrochloride, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms,, Metastatic Cancer,
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally…
- Conditions
- Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, Advanced Solid Malignancies
- Trial name
- NCT01605916
- Testing
- AZD6244
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Lung Adenocarcinoma, Stage I
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks
- Trial name
- NCT03254004
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Both pemetrexed and erlotinib are second-line treatment options for patients with advanced non-small cell lung cancer. It is controversial that whether it is necessary to detect epidermal growth factor receptor (EGFR) mutation…
- Trial name
- NCT01565538
- Testing
- Erlotinib, Pemetrexed
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Si-Yu Wang
Small Cell Lung Cancer
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
This study is a single arm, multi-center phase II study of durvalumab and AZD6738 combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.
- Trial name
- SUKSES-N4 (NCT04361825)
- Testing
- Durvalumab
- Where
- 2 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- Se-Hoon Lee
Nonsmall Cell Lung Cancer
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
Based on the efficacy of immunotherapies in advanced disease with a reasonable safety profile/tolerability we could hypothesize that, immunotherapy should work best in the situation of minimal residual disease, Two clinical…
- Trial name
- PRINCEPS (NCT02994576)
- Testing
- Atezolizumab
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non Small Cell Lung Carcinoma
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
- Trial name
- NCT00080340
- Testing
- TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
- Where
- 338 sites in United States, Argentina and 6 more
- Volunteers
- 520 people
- Sponsor
- Telik
Lung Cancer, Adenocarcinoma of the Lung
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
The purpose of this study is to find out what effects (good and bad) a tumor vaccine (GM.CD40L) used in combination with Nivolumab will have on participants and their cancer.
- Trial name
- NCT02466568
- Testing
- Nivolumab, GM.CD40L Vaccine
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Carcinoma
Lung Cancer Risk Assessment and Etiology
This study examines the biological and social determinants that may increase the risk for lung cancer in patients and never-smoking individuals.
- Trial name
- NCT06328621
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lung Cancer
Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers
The study duration is 12 months. The initial enrollment visit will take approximately one hour. The Month 1, 3, 6, 7, 9 and 12 visits will take approximately 30 minutes each.
- Trial name
- Omega (NCT03936621)
- Testing
- Omega 3 fatty acid
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.